Pulmonx Q2 revenue $17.2M (+23% YoY), raises FY2023 guidance to $64-66M

Pulmonx Corp

2023-Q2 EPS reported -$0.85 revenue$31,729,000

Record worldwide revenue $17.2M, up 23% YoY; US revenue $11.0M up 28% YoY.
Gross margin 74% (vs 75% prior year); net loss $16.2M ($0.43/share).
Raised 2023 revenue guidance to $64-66M (from $63-65M); operating expenses maintained at $112-114M.
Added 15 new US Zephyr Valve treatment centers in Q2.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Pulmonx Corp reported second quarter of 2023 ended June 30, 2023 results: revenue $17.2 million, net income $16.2 million, EPS $0.43 per share. Guidance raised.

Period: second quarter of 2023 ended June 30, 2023
Revenue: $17.2 million
Net income: $16.2 million
EPS: $0.43 per share
Guidance: raised
Result: reported results

Exact text from the filing

treatments for lung disease, today reported financial results for the second quarter of 2023 ended June 30, 2023. Recent Highlights • Achieved record worldwide revenue of $17.2 million in the second quarter of 2023, a 23% increase over the same period last year • Delivered a new high of $11.0 million in U.S. revenue in the second quarter of 2023, representing

View on SEC.gov

Browse all earnings releases →

Pulmonx Corp filing history →

Source: SEC EDGAR

accession 0001127537-23-000032

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.